Related Experiment Video

Updated: Jun 21, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized

YongLi Zheng1, LianSan Zhao, TaiXiang Wu

  • 1Infectious Disease Centre, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan Province, PR China. zhyl1973@live.com

Virology Journal
|July 10, 2009
PubMed

Insights

Consensus interferon (CIFN) showed comparable efficacy to interferon alpha-1b in treating chronic hepatitis B. Both treatments gradually improved liver enzymes and reduced viral DNA and HBeAg levels.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Consensus interferon (CIFN) is a novel type I interferon formulation.
  • Chronic hepatitis B infection remains a significant global health concern, particularly HBeAg-positive cases.

Purpose of the Study:

  • To evaluate the efficacy of CIFN compared to interferon alpha-1b (IFN-alpha1b) in treating HBeAg-positive chronic hepatitis B.
  • To assess treatment outcomes including serological, virological, and biochemical parameters.

Main Methods:

  • A multicentre, controlled trial involving 144 patients with HBeAg-positive chronic hepatitis B.
  • Randomized assignment to receive either 9 microg CIFN or 50 microg IFN-alpha1b subcutaneously three times weekly for 24 weeks.
  • Efficacy assessment based on normalization of ALT levels and undetectable HBV DNA or HBeAg at the end of treatment and 24 weeks post-treatment.

Main Results:

  • No statistically significant differences were observed in serological, virological, or biochemical parameters between the CIFN and IFN-alpha1b groups.
  • Similar rates of complete or partial response were noted at the end of treatment and during the follow-up period for both groups (p > 0.05).

Conclusions:

  • The study suggests that 9 microg CIFN is an effective treatment option for HBeAg-positive chronic hepatitis B.
  • CIFN demonstrated the ability to induce gradual ALT normalization, HBV DNA clearance, and HBeAg loss or seroconversion.
Abstract

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...